An ischemic stroke occurs when blood clots or other particles block the blood vessels to the brain. Stroke is one of the leading causes of disability worldwide, with approximately one-third to one-half of stroke survivors left with permanent disability. These individuals can experience an array of disabilities, including decreased mobility. This “permanent” disability results in a loss in independence and quality of life. Further, the emotional trauma of being left dependent on others due to disability often additionally leads to depression and anxiety.
Unfortunately, everyone’s brain does not heal the same. Some people will experience complete repair post-stroke while others will not. Despite advancements in other fields, there remains a gap in sufficient post-stroke treatment: i.e. a device that can enhance the natural reparative process. In this regard, you can think of CELLTech™ as working similar to how an implantable pacemaker enhances the natural heartbeat after a heart attack.
This is the reason our team is committed to designing and developing our patented technology, CELLTech™, to be safely and effectively used in treating subacute ischemic stroke. While CELLTech™ may be tested to treat additional indications, the first indication is subacute ischemic stroke.